ストックスクリーナーアプリを入手
38.30
0.98%
0.37
アフターアワーズ：
37.50
-0.80
-2.09%
前日終値:
$37.93
開ける：
$38.55
24時間の取引高:
3.71M
Relative Volume:
1.74
時価総額：
$4.53B
収益：
$1.29B
当期純損益:
$251.00M
株価収益率:
19.40
EPS:
1.9744
ネットキャッシュフロー:
$-193.86M
1週間 パフォーマンス:
+0.45%
1か月 パフォーマンス:
+4.82%
6か月 パフォーマンス:
+7.77%
1年 パフォーマンス:
+175.54%
1日の値動き範囲:
$37.85
$39.05
1週間の範囲:
$37.71
$39.05
52週間の値動き範囲:
$13.45
$41.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
38.30 | 4.53B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Indivior gains new overweight at Barclays on business turnaround - MSN
Indivior stock gains new Overweight at Barclays (INDV:NASDAQ) - Seeking Alpha
Barclays Initiates Indivior at Overweight With $46 Price Target - marketscreener.com
Indivior PLC (INDV) Institutional Confidence - TradingKey
How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan - Yahoo Finance
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? - Yahoo Finance
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now? - Insider Monkey
Recent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's why - MSN
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior (INDV) Chief Scientific Officer sells 18,586 shares under 10b5-1 plan - Stock Titan
Is Indivior Stock a Buy After Higher 2026 Guidance? - The Globe and Mail
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026 - Yahoo Finance
INDV Stock: What Sublocade Growth Signals for 2026 - Yahoo Finance
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
INDV News | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Indivior Pharmaceuticals Inc. (INDV) is a great momentum stock: Should you buy? - MSN
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - The Globe and Mail
[144] Indivior Pharmaceuticals, Inc. SEC Filing - Stock Titan
A Look At Indivior Pharmaceuticals (INDV) Valuation After Strong Multi Period Share Price Gains - Yahoo Finance
Indivior CFO Ryan Preblick sells $1.36m in company stock By Investing.com - Investing.com Australia
Indivior Pharmaceuticals Inc (INDV) CFO Ryan Preblick Sells 36,0 - GuruFocus
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
Indivior CFO Ryan Preblick sells $1.36m in company stock - Investing.com
Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing - Moomoo
[Form 4] Indivior Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Indivior: A Stronger Business Than When I First Covered It (NASDAQ:INDV) - Seeking Alpha
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Recent Share Price Cooling - Sahm
Amended Form 144: INDV (NASDAQ: INDV) lists 36,000-share sale via Fidelity - Stock Titan
INDV (NASDAQ) proposes sale of 36,000 shares; $1.36M aggregate listed - Stock Titan
These healthcare stocks have maintained strong buy ratings for months - MSN
Indivior Pharmaceuticals, Inc. Statistics – LSX:A42086 - TradingView
Indivior (INDV) Hovers Near Resistance Amid Modest Gains – Key Levels in FocusOrder Block - newsline.com
Indivior Pharmaceuticals (INDV) Holds Steady Near Key Support Amidst Cautious TradingIchimoku Entry - newsline.com
Operating expenses (excl. COGS) of Indivior Pharmaceuticals, Inc. – XETR:E7P - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
Indivior PLC stock (GB00BYZ0C031): shares trade quietly as investors focus on valuation metrics - AD HOC NEWS
Analysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV) - The Globe and Mail
INDV Technical Analysis | Trend, Signals & Chart Patterns | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Indivior Pharmaceuticals Inc (INDV) Stock Up 5.1% but GF Value S - GuruFocus
Net margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Quick ratio of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted net income available to common stockholders of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
After tax other income/expense of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Non-controlling/minority interest of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Book value per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Operating income of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted earnings per share (diluted EPS) of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Indivior Pharmaceuticals, Inc. Income Statement – LSX:A42086 - TradingView
Total debt per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
11.23%
0.45%
大文字化:
|
ボリューム (24 時間):